Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.57
NAS:ARRY's Cash-to-Debt is ranked lower than
74% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:ARRY: 1.57 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ARRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.67 Max: No Debt
Current: 1.57
Equity-to-Asset 0.11
NAS:ARRY's Equity-to-Asset is ranked lower than
88% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:ARRY: 0.11 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ARRY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.55  Med: 0.22 Max: 0.93
Current: 0.11
-1.55
0.93
Piotroski F-Score: 5
Altman Z-Score: -1.01
Beneish M-Score: -3.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -61.17
NAS:ARRY's Operating Margin % is ranked higher than
56% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:ARRY: -61.17 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ARRY' s Operating Margin % Range Over the Past 10 Years
Min: -410.11  Med: -89.25 Max: 6.34
Current: -61.17
-410.11
6.34
Net Margin % -70.03
NAS:ARRY's Net Margin % is ranked higher than
55% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:ARRY: -70.03 )
Ranked among companies with meaningful Net Margin % only.
NAS:ARRY' s Net Margin % Range Over the Past 10 Years
Min: -511.63  Med: -116.55 Max: 18.05
Current: -70.03
-511.63
18.05
ROA % -52.93
NAS:ARRY's ROA % is ranked lower than
66% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:ARRY: -52.93 )
Ranked among companies with meaningful ROA % only.
NAS:ARRY' s ROA % Range Over the Past 10 Years
Min: -99.03  Med: -50.67 Max: 5.6
Current: -52.93
-99.03
5.6
ROC (Joel Greenblatt) % -1077.14
NAS:ARRY's ROC (Joel Greenblatt) % is ranked lower than
57% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:ARRY: -1077.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ARRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1397.54  Med: -273.72 Max: 297.05
Current: -1077.14
-1397.54
297.05
3-Year Revenue Growth Rate 14.30
NAS:ARRY's 3-Year Revenue Growth Rate is ranked higher than
64% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:ARRY: 14.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ARRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -2.7 Max: 39.8
Current: 14.3
-35.9
39.8
3-Year EBITDA Growth Rate 9.40
NAS:ARRY's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:ARRY: 9.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ARRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: 0.7 Max: 105.1
Current: 9.4
-66.3
105.1
3-Year EPS without NRI Growth Rate 4.50
NAS:ARRY's 3-Year EPS without NRI Growth Rate is ranked higher than
59% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:ARRY: 4.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ARRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: 0.7 Max: 55.7
Current: 4.5
-50.5
55.7
GuruFocus has detected 2 Warning Signs with Array BioPharma Inc $NAS:ARRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ARRY's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ARRY Guru Trades in Q2 2016

Ken Fisher 135,695 sh (unchged)
Jim Simons 17,452 sh (-99.19%)
» More
Q3 2016

ARRY Guru Trades in Q3 2016

Joel Greenblatt 16,705 sh (New)
Paul Tudor Jones 135,000 sh (New)
Jim Simons 424,452 sh (+2332.11%)
Ken Fisher 135,895 sh (+0.15%)
» More
Q4 2016

ARRY Guru Trades in Q4 2016

Steven Cohen 1,570,641 sh (New)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Ken Fisher 65,693 sh (-51.66%)
» More
Q1 2017

ARRY Guru Trades in Q1 2017

Caxton Associates 15,900 sh (New)
Ken Fisher 78,014 sh (+18.76%)
Steven Cohen 500,000 sh (unchged)
Steven Cohen 1,277,900 sh (-18.64%)
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:PBYI, NAS:BGNE, NAS:CORT, NAS:RGEN, NAS:GBT, NAS:INVA, NAS:LXRX, NAS:BPMC, NYSE:EBS, NAS:AAAP, NAS:LOXO, NAS:DERM, NAS:ONCE, NAS:CHRS, NAS:HALO, OTCPK:BVNRY, NYSE:CBM, NAS:FOLD, NAS:DBVT, OTCPK:GNFTF » details
Traded in other countries:AR2.Germany,
Headquarter Location:USA
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company's proprietary clinical programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (partnered with AstraZeneca. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of oncology and other indications. The Company competes with companies that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.

Ratios

vs
industry
vs
history
PB Ratio 51.90
ARRY's PB Ratio is ranked lower than
96% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ARRY: 51.90 )
Ranked among companies with meaningful PB Ratio only.
ARRY' s PB Ratio Range Over the Past 10 Years
Min: 3.52  Med: 10.9 Max: 107.8
Current: 51.9
3.52
107.8
PS Ratio 8.19
ARRY's PS Ratio is ranked higher than
60% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ARRY: 8.19 )
Ranked among companies with meaningful PS Ratio only.
ARRY' s PS Ratio Range Over the Past 10 Years
Min: 1.44  Med: 7.26 Max: 24.4
Current: 8.19
1.44
24.4
EV-to-EBIT -13.64
ARRY's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ARRY: -13.64 )
Ranked among companies with meaningful EV-to-EBIT only.
ARRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -44  Med: -5.9 Max: 320.9
Current: -13.64
-44
320.9
EV-to-EBITDA -13.88
ARRY's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ARRY: -13.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -76.5  Med: -6.5 Max: 165.9
Current: -13.88
-76.5
165.9
Current Ratio 3.47
ARRY's Current Ratio is ranked higher than
51% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ARRY: 3.47 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.96 Max: 7.86
Current: 3.47
0.81
7.86
Quick Ratio 3.47
ARRY's Quick Ratio is ranked higher than
52% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ARRY: 3.47 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.94 Max: 7.55
Current: 3.47
0.81
7.55
Days Sales Outstanding 74.03
ARRY's Days Sales Outstanding is ranked lower than
68% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ARRY: 74.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.06  Med: 47.09 Max: 497.21
Current: 74.03
2.06
497.21
Days Payable 92.10
ARRY's Days Payable is ranked higher than
60% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ARRY: 92.10 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 92.1
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.10
ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ARRY: -7.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.8 Max: -4.2
Current: -7.1
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 76.91
ARRY's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ARRY: 76.91 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARRY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.24  Med: 5.66 Max: 76.91
Current: 76.91
2.24
76.91
Price-to-Tangible-Book 52.88
ARRY's Price-to-Tangible-Book is ranked lower than
93% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ARRY: 52.88 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.14  Med: 4.21 Max: 102.93
Current: 52.88
1.14
102.93
Price-to-Median-PS-Value 1.13
ARRY's Price-to-Median-PS-Value is ranked lower than
59% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ARRY: 1.13 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.91 Max: 3.06
Current: 1.13
0.2
3.06
Earnings Yield (Greenblatt) % -7.31
ARRY's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ARRY: -7.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.66  Med: 2.2 Max: 5.1
Current: -7.31
-7.66
5.1

More Statistics

Revenue (TTM) (Mil) $160.3
EPS (TTM) $ -0.73
Beta1.77
Short Percentage of Float18.34%
52-Week Range $3.10 - 13.40
Shares Outstanding (Mil)170.80
» More Articles for NAS:ARRY

Headlines

Articles On GuruFocus.com
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017 May 10 2017 
Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Bin May 09 2017 
Array BioPharma Announces Strategic Collaboration with Merck May 08 2017 
Array Biopharma To Report Financial Results For The Third Quarter Of Fiscal 2017 On May 10, 2017 May 03 2017 
Shalini Sharp Joins Array BioPharma Board of Directors Apr 27 2017 
Screen: Stocks With Estimated Revenue Up 5% - January Jan 18 2016 
Insider Buys Round-up: Tenet Healthcare and Sprint Corp Aug 14 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 

More From Other Websites
Blog Coverage: Mirna Announced Reverse Merger Agreement May 17 2017
Edited Transcript of ARRY earnings conference call or presentation 10-May-17 1:00pm GMT May 16 2017
Today's Research Reports on Stocks to Watch: Array Biopharma and Verastem May 11 2017
Array Biopharma Sees Positive Study Results From COLUMBUS Phase 2, But Commercialization May Prove... May 10 2017
Here's Why the Market's Overlooking Array Biopharma Inc.'s Earnings Miss Today May 10 2017
Investor Network: Array BioPharma Inc. to Host Earnings Call May 10 2017
Array BioPharma reports 3Q loss May 10 2017
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017 May 10 2017
Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of... May 09 2017
Array BioPharma Announces Strategic Collaboration with Merck May 08 2017
Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma May 03 2017
Array Biopharma To Report Financial Results For The Third Quarter Of Fiscal 2017 On May 10, 2017 May 03 2017
Shalini Sharp Joins Array BioPharma Board of Directors Apr 27 2017
If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss Apr 20 2017
Today's Research Reports on Biotech Stocks to Watch: Array Biopharma and ImmunoGen Apr 17 2017
Do Options Traders Know Something About Array BioPharma (ARRY) Stock We Don't? Apr 07 2017
Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down Mar 22 2017
Will Array Biopharma's Melanoma Drugs Keep the Stock Soaring? Mar 22 2017
How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More Mar 20 2017
Array Biopharma Withdraws Cancer Drug Application Mar 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat